About Regeneron Pharmaceuticals, Inc.
https://www.regeneron.comRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
CEO
Leonard S. Schleifer
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 947
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Canaccord Genuity
Buy
Citigroup
Buy
Guggenheim
Buy
Jefferies
Buy
Truist Securities
Buy
Goldman Sachs
Buy
Grade Summary
Showing Top 6 of 20
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:9.05M
Value:$6.82B
BLACKROCK, INC.
Shares:8.84M
Value:$6.66B
BLACKROCK INC.
Shares:8.45M
Value:$6.37B
Summary
Showing Top 3 of 1,649
About Regeneron Pharmaceuticals, Inc.
https://www.regeneron.comRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.75B ▲ | $2.21B ▲ | $1.46B ▲ | 38.89% ▲ | $14.09 ▲ | $1.92B ▲ |
| Q2-2025 | $3.68B ▲ | $2.07B ▲ | $1.39B ▲ | 37.86% ▲ | $13.24 ▲ | $1.66B ▲ |
| Q1-2025 | $3.03B ▼ | $1.97B ▼ | $808.7M ▼ | 26.7% ▲ | $7.58 ▼ | $1.04B ▼ |
| Q4-2024 | $3.79B ▲ | $2.23B ▲ | $917.7M ▼ | 24.22% ▼ | $8.53 ▼ | $1.09B ▼ |
| Q3-2024 | $3.72B | $2.05B | $1.34B | 36.03% | $12.4 | $1.63B |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $8.44B ▲ | $40.17B ▲ | $9.21B ▲ | $30.96B ▲ |
| Q2-2025 | $7.47B ▼ | $38.22B ▲ | $8.28B ▲ | $29.94B ▲ |
| Q1-2025 | $8.35B ▼ | $37.55B ▼ | $8.16B ▼ | $29.39B ▲ |
| Q4-2024 | $9.01B ▼ | $37.76B ▲ | $8.41B ▲ | $29.35B ▲ |
| Q3-2024 | $9.8B | $37.44B | $8.12B | $29.33B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.46B ▲ | $1.62B ▲ | $-402.9M ▲ | $-717.9M ▲ | $497.5M ▲ | $1.42B ▲ |
| Q2-2025 | $1.39B ▲ | $1.14B ▲ | $-1.09B ▼ | $-1.13B ▼ | $-1.08B ▼ | $967.6M ▲ |
| Q1-2025 | $808.7M ▼ | $1.05B ▼ | $647.5M ▲ | $-1.09B ▲ | $604M ▲ | $773.6M ▼ |
| Q4-2024 | $917.7M ▼ | $1.26B ▼ | $350.6M ▲ | $-1.14B ▼ | $477.2M ▲ | $995.8M ▼ |
| Q3-2024 | $1.34B | $1.29B | $-574.4M | $-634M | $83.6M | $1.11B |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Collaboration Revenue | $1.61Bn ▲ | $1.53Bn ▼ | $1.86Bn ▲ | $1.97Bn ▲ |
 Product | $2.00Bn ▲ | $1.42Bn ▼ | $1.63Bn ▲ | $1.59Bn ▼ |
 Product and Service Other | $180.00M ▲ | $80.00M ▼ | $180.00M ▲ | $200.00M ▲ |
CEO
Leonard S. Schleifer
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 947
Ratings Snapshot
Rating : A
Most Recent Analyst Grades
Canaccord Genuity
Buy
Citigroup
Buy
Guggenheim
Buy
Jefferies
Buy
Truist Securities
Buy
Goldman Sachs
Buy
Grade Summary
Showing Top 6 of 20
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:9.05M
Value:$6.82B
BLACKROCK, INC.
Shares:8.84M
Value:$6.66B
BLACKROCK INC.
Shares:8.45M
Value:$6.37B
Summary
Showing Top 3 of 1,649